All Articles

Epigenetics firm VolitionRx expands commercial reach with strategic alliances and promising financial results, navigating a competitive market with innovative diagnostic technologies.

As CBD gains popularity, a growing need exists for informed patient-doctor discussions. One company is stepping up to bridge the knowledge gap and empower better healthcare conversations.

YouWare is democratizing app creation with its “vibe coding” approach, attracting substantial investment and challenging established no-code platforms. Can this new approach truly unlock creativity for everyone?

Positive Phase 2 data for Elicio Therapeutics' ELI-002 7P in pancreatic cancer, combined with a bolstered cash position, positions the company for growth in the competitive immunotherapy landscape.

Medical device firm GlucoTrack plans pivotal FDA submission for its fully implantable glucose monitor, boasting a three-year lifespan & direct blood glucose measurement. The company is strengthening its financial position to support upcoming trials.

Clinical-stage biotech NuCana plc bolsters its cash runway to 2029 while demonstrating promising data for its ProTide cancer therapies, NUC-7738 and NUC-3373, offering hope for patients with difficult-to-treat cancers.

Spero Therapeutics’ tebipenem HBr shows promising Phase 3 results, offering a potential first-in-class oral treatment for complicated urinary tract infections and a new lifeline against antibiotic resistance.

QUELIMMUNE maker SeaStar Medical reports improved financials and encouraging clinical trial progress for its novel AKI prevention platform. The company is focusing on addressing a critical gap in care for acute kidney injury.

Fennec Pharmaceuticals reports strong Q3 2025 results fueled by PEDMARK®, the first FDA-approved therapy for cisplatin-induced hearing loss. Expansion into Europe and Japan signals a bright future, but supply chain vulnerabilities loom.

Positive Phase 3 data and expanding applications for Reviva Pharmaceuticals’ brilaroxazine signal a potential breakthrough for schizophrenia treatment and open doors to new markets like pulmonary fibrosis and psoriasis.

Profound Medical Corp. secures a key distribution agreement in Saudi Arabia as it continues to commercialize its TULSA PRO system for BPH. The company's financial position remains under scrutiny amid ongoing investment in growth.

Facing clinical trial disappointments with its depression drug, Relmada Therapeutics is shifting focus to a promising bladder cancer treatment, NDV-01, while also advancing a program for compulsive disorders. Investors are watching closely.

Despite a revenue dip, Strata Skin Sciences is strategically positioning itself for growth with expanded CPT codes and a focus on recurring revenue. The company's innovative XTRAC system and new TheraClearX device are key to its long-term prospects.

The Air Canada Foundation is expanding its grant program for 2026, allocating $1.6M in 2025 to support Canadian charities focused on improving the health and well-being of children and youth. The Foundation is increasingly prioritizing underserved communities.

ORIC Pharmaceuticals is making strides in metastatic castration-resistant prostate cancer with its PRC2 inhibitor, ORIC-944, and brain-penetrant lung cancer therapy, enozertinib, bolstered by a strong financial position.

A new wave of grants is empowering high school culinary programs, equipping students with skills and experience to fill critical labor gaps in the restaurant industry. Here’s how.

Positive preclinical data for JADE101 and progress on JADE201 have secured a significant investment for Jade Biosciences, positioning the company to advance its autoimmune disease pipeline.

Positive clinical trial results for telitacicept in Sjögren's disease and continued promise in myasthenia gravis, coupled with a significant capital raise, position Vor Bio for potential growth – despite substantial net losses.

A Northern California airport is leading the charge in energy innovation, using electric vehicles to power critical infrastructure and stabilize the grid. This project signals a shift towards a more resilient, sustainable energy future.

Forbes recognizes Graybar as one of America’s Most Trusted Companies, citing its unwavering commitment to customers, employees, and a robust supply chain in challenging times.